Key result
Implantable cardioverter defibrillators provide a significant survival benefit in patients with ischemic or idiopathic dilated cardiomyopathy and an ejection fraction ≤35%.
Why the study?
Does the implantable cardioverter defibrillator (ICD) improve survival in patients with ischemic or idiopathic dilated cardiomyopathy and an EF ≤35%?
Population
Patients who have survived a sudden cardiac death episode or are at high risk of developing SCD…
Design
Review
Authors
Loading...
Reinforces ICD benefit in indicated cardiomyopathy patients; leaves open refinement of selection with modern GDMT.
Does the implantable cardioverter defibrillator (ICD) improve survival in patients with ischemic or idiopathic dilated cardiomyopathy and an EF ≤35%?
ICDs provide a well-established survival benefit for patients with ischemic or idiopathic dilated cardiomyopathy and an EF ≤35% when added to maximal medical therapy.
David S. Cannom (2005) conducted a review in Sudden cardiac death. Implantable cardioverter defibrillator (ICD) was evaluated. Implantable cardioverter defibrillators provide a significant survival benefit in patients with ischemic or idiopathic dilated cardiomyopathy and an ejection fraction ≤35%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: